| Description | CTP499, a selective PDE inhibitor, and the deuterium-containing agent is an HDX analogue and a metabolite of hexantheobromine that slows the progression of type 2 diabetic nephropathy in patients with macroalbuminuria. |
| molecular weight | 285.35 |
| Molecular formula | C13H20N4O3 |
| CAS | 1268605-91-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B. Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade. J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review. PubMed PMID: 26239562; PubMed Central PMCID: PMC4485003. 2. Tang X, Bridson G, Ke J, Wu L, Erol H, Graham P, Lin CH, Braman V, Zhao H, Liu JF, Lin ZJ, Cheng C. Quantitative analyses of CTP-499 and five major metabolites by core-structure analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 15;963:1-9. doi: 10.1016/j.jchromb.2014.05.043. Epub 2014 May 28. PubMed PMID: 24927417. 3. Braman V, Graham P, Cheng C, Turnquist D, Harnett M, Sabounjian L, Shipley J. A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. Clin Pharmacol Drug Dev. 2013 Jan;2(1):53-66. doi: 10.1002/cpdd.3. Epub 2013 Feb 21. PubMed PMID: 27121560. |